research use only
Cat.No.S7217
| Related Targets | JAK TGF-beta/Smad Wnt/beta-catenin ERK GSK-3 ROCK Hedgehog/Smoothened PKA Secretase STAT |
|---|---|
| Other OCT Inhibitors | O4I2 O4I1 OAC2 |
|
In vitro |
DMSO
: 47 mg/mL
(198.09 mM)
Ethanol : 21 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 237.26 | Formula | C14H11N3O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 300586-90-7 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | BAS 00287861 | Smiles | C1=CC=C(C=C1)C(=O)NC2=NC=C3C(=C2)C=CN3 | ||
| Targets/IC50/Ki |
Oct4
|
|---|---|
| In vitro |
OAC1 at 1 μM enhances reprogramming efficiency by activating both Oct4 and Nanog promoter-driven luciferase reporter genes. Furthermore, this compound enhances the pluripotent stem cells (iPSC) reprogramming efficiency and accelerates the reprogramming process in the quartet reprogramming factors (Oct4, Sox2, c-Myc, and Klf4) treated mouse embryonic fibroblasts (MEFs). The iPSC colonies derived using it along with the quartet factors exhibits typical ESC morphology, gene-expression pattern, and developmental potential. It seems to enhance reprogramming efficiency via increasing transcription of the Oct4-Nanog-Sox2 triad and Tet1, a gene known to be involved in DNA demethylation. While it doesn’t inhibit the p53-p21 pathway or activate the Wnt-β-catenin signaling. This chemical may be used to enhance the reprogramming of somatic cells to a pluripotent state.
|
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01161836 | Completed | Advanced Solid Tumors |
Sanofi |
July 2010 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.